To avoid the bias from the analysis of only mRNA expression data, we examined the PRMT2 protein levels in vivo by immunohistochemistry (IHC) staining of 21 cases of resected tumor samples representing different grades of glioma (the clinical information of the samples is listed in Supplementary Table 1). This evidence concerns the gene PRMT2 and neoplasm.